Differential regulation of VEGF by TGF-β and hypoxia in rat proximal tubular cells

American Journal of Physiology - Renal Physiology

Volumn 287, Issue 4 56-4, 2004, Pages

  Nakagawa, Takahiko ^a,b   Lan, Hui Y ^b   Zhu, Hong J ^c   Kang, Duk Hee ^d   Schreiner, George F ^e   Johnson, Richard J ^a,b  

^a UNIVERSITY OF FLORIDA   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

^d Ewha Womans University   (South Korea)

^e SCIOS INC   (United States)

Author keywords

Angiogenesis; Mitogen activated protein kinase; Protein kinase C; Renal; Smad; Transforming growth factor ; Vascular endothelial growth factor

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; COMPLEMENTARY DNA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE C; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; GENE OVEREXPRESSION; HYPOXIA; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE; NONHUMAN; PRIORITY JOURNAL; RAT; WESTERN BLOTTING;

EID: 4644298996     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00040.2004     Document Type: Article

References (40)

1. 2 and Smad proteins in human endothelial cells. Blood 98: 3324-3331, 2001.
2. Berra E, Pages G, and Pouyssegur J. MAP kinases and hypoxia in the control of VEGF expression. Cancer Metastasis Rev 19: 139-145, 2000.
3. Boussat S, Eddahibi S, Coste A, Fataccioli V, Gouge M, Housset B, Adnot S, and Maitre B. Expression and regulation of vascular endothelial growth factor in human pulmonary epithelial cells. Am J Physiol Lung Cell Mol Physiol 279: L371-L378, 2000.
4. Brogi E, Schatteman G, Wu T, Kim EA, Varticovski L, Keyt B, and Isner JM. Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression. J Clin Invest 97: 469-476, 1996.
5. 1-induced expression of vascular endothelial growth factor in murine osteoblastic MC3T3-E1 cells. Biochim Biophys Acta 1497: 69-76, 2000.
6. Cooper ME, Vranes D, Youssef S, Stacker SA, Cox AJ, Rizkalla B, Casley DJ, Bach LA, Kelly DJ, and Gilbert RE. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 48: 2229-2239, 1999.
7. De Vriese AS, Tilton RG, Elger M, Stephan CC, Kriz W, and Lameire NH. Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes. J Am Soc Nephrol 12: 993-1000, 2001.
8. El Awad B, Kreft B, Wolber EM, Hellwig-Burgel T, Metzen E, Fandrey J, and Jelkmann W. Hypoxia and interleukin-1β stimulate vascular endothelial growth factor production in human proximal tubular cells. Kidney Int 58: 43-50, 2000.
9. Flyvbjerg A, Dagnaes-Hansen F, De Vriese AS, Schrijvers BF, Tilton RG, and Rasch R. Amelioration of long-term renal changes in obese type 2 diabetic mice by a neutralizing vascular endothelial growth factor antibody. Diabetes 51: 3090-3094, 2002.
10. Horita Y, Miyazaki M, Koji T, Kobayashi N, Shibuya M, Razzaque MS, Cheng M, Ozono Y, Kohno S, and Taguchi T. Expression of vascular endothelial growth factor and its receptors in rats with protein-overload nephrosis. Nephrol Dial Transplant 13: 2519-2528, 1998.
11. Kang DH, Anderson S, Kim YG, Mazzalli M, Suga S, Jefferson JA, Gordon KL, Oyama TT, Hughes J, Hugo C, Kerjaschki D, Schreiner GF, and Johnson RJ. Impaired angiogenesis in the aging kidney: vascular endothelial growth factor and thrombospondin-1 in renal disease. Am J Kidney Dis 37: 601-611, 2001.
12. Kang DH, Hughes J, Mazzali M, Schreiner GF, and Johnson RJ. Impaired angiogenesis in the remnant kidney model. II. Vascular endothelial growth factor administration reduces renal fibrosis and stabilizes renal function. J Am Soc Nephrol 12: 1448-1457, 2001.
13. Kang DH, Joly AH, Oh SW, Hugo C, Kerjaschki D, Gordon KL, Mazzali M, Jefferson JA, Hughes J, Madsen KM, Schreiner GF, and Johnson RJ. Impaired angiogenesis in the remnant kidney model. I. Potential role of vascular endothelial growth factor and thrombospondin-1. J Am Soc Nephrol 12: 1434-1447, 2001.
14. Kang DH, Kim YG, Andoh TF, Gordon KL, Suga S, Mazzali M, Jefferson JA, Hughes J, Bennett W, Schreiner GF, and Johnson RJ. Post-cyclosporine-mediated hypertension and nephropathy: amelioration by vascular endothelial growth factor. Am J Physiol Renal Physiol 280: F727-F736, 2001.
15. Kang DH, Nakagawa T, Feng L, and Johnson RJ. Nitric oxide modulates vascular disease in the remnant kidney model. Am J Pathol 161: 239-248, 2002.
16. Kim BS, Chen J, Weinstein T, Noiri E, and Goligorsky MS. VEGF expression in hypoxia and hyperglycemia: reciprocal effect on branching angiogenesis in epithelial-endothelial co-cultures. J Am Soc Nephrol 13: 2027-2036, 2002.
17. Kim YG, Suga SI, Kang DH, Jefferson JA, Mazzali M, Gordon KL, Matsui K, Breiteneder-Geleff S, Shankland SJ, Hughes J, Kerjaschki D, Schreiner GF, and Johnson RJ. Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy. Kidney Int 58: 2390-2399, 2000.
18. Kirk SL and Karlik SJ. VEGF and vascular changes in chronic neuroinflammation. J Autoimmun 21: 353-363, 2003.
19. Kumar S, McDonnell PC, Gum RJ, Hand AT, Lee JC, and Young PR. Novel homologue of CSBP/p38 MAP kinase: activation, substrate specificity and sensitivity to inhibition by pyridinyl imidazoles. Biochem Biophys Res Commun 235: 533-538, 1997.
20. Lemstrom KB, Krebs R, Nykanen AI, Tikkanen JM, Sihvola RK, Aaltola EM, Hayry PJ, Wood J, Alitalo K, Yla-Herttuala S, and Koskinen PK. Vascular endothelial growth factor enhances cardiac allograft arteriosclerosis. Circulation 105: 2524-2530, 2002.
21. Ling H, Li X, Jha S, Wang W, Karetskaya L, Pratt B, and Ledbetter S. Therapeutic role of TGF-β-neutralizing antibody in mouse cyclosporin A nephropathy: morphologic improvement associated with functional preservation. J Am Soc Nephrol 14: 377-388, 2003.
22. McCourt M, Wang JH, Sookhai S, and Redmond HP. Proinflammatory mediators stimulate neutrophil-directed angiogenesis. Arch Surg 134: 1325-1331, 1999.
23. Mottet D, Michel G, Renard P, Ninane N, Raes M, and Michiels C. Role of ERK and calcium in the hypoxia-induced activation of HIF-1. J Cell Physiol 194: 30-44, 2003.
24. Nagineni CN, Samuel W, Nagineni S, Pardhasaradhi K, Wiggert B, Detrick B, and Hooks JJ. Transforming growth factor-β induces expression of vascular endothelial growth factor in human retinal pigment epithelial cells: involvement of mitogen-activated protein kinases. J Cell Physiol 197: 453-462, 2003.
25. Nakagawa T, Li JH, Garcia G, Mu W, Piek E, Bottinger EP, Chen Y, Zhu HJ, Kang DH, Schreiner GF, Lan HY, and Johnson RJ. TGF-β induces proangiogenic and antiangiogenic factor via parallel but distinct pathways. Kidney Int. In press.
26. Namiki A, Brogi E, Kearney M, Kim EA, Wu T, Couffinhal T, Varticovski L, and Isner JM. Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells. J Biol Chem 270: 31189-31195, 1995.
27. Norman JT, Clark IM, and Garcia PL. Hypoxia promotes fibrogenesis in human renal fibroblasts. Kidney Int 58: 2351-2366, 2000.
28. 1-independent mechanism. Kidney Int 52: 637-647, 1997.
29. Park SY, Lee H, Hur J, Kim SY, Kim H, Park JH, Cha S, Kang SS, Cho GJ, Choi WS, and Suk K. Hypoxia induces nitric oxide production in mouse microglia via p38 mitogen-activated protein kinase pathway. Brain Res Mol Brain Res 107: 9-16, 2002.
30. Sanchez-Elsner T, Botella LM, Velasco B, Corbi A, Attisano L, and Bernabeu C. Synergistic cooperation between hypoxia and transforming growth factor-β pathways on human vascular endothelial growth factor gene expression. J Biol Chem 276: 38527-38535, 2001.
31. Sanchez-Elsner T, Botella LM, Velasco B, Langa C, and Bernabeu C. Endoglin expression is regulated by transcriptional cooperation between the hypoxia and transforming growth factor-β pathways. J Biol Chem 277: 43799-43808, 2002.
32. Sanchez-Elsner T, Ramirez JR, Rodriguez-Sanz F, Varela E, Bernabeu C, and Botella LM. A cross-talk between hypoxia and TGF-β orchestrates erythropoietin gene regulation through SP1 and Smads. J Mol Biol 336: 9-24, 2004.
33. 3, a growth factor involved in trophoblast differentiation. Placenta 24: 941-950, 2003.
34. Shemirani B and Crowe DL. Hypoxic induction of HIF-1α and VEGF expression in head and neck squamous cell carcinoma lines is mediated by stress activated protein kinases. Oral Oncol 38: 251-257, 2002.
35. Shih SC and Claffey KP. Role of AP-1 and HIF-1 transcription factors in TGF-β activation of VEGF expression. Growth Factors 19: 19-34, 2001.
36. 1 in experimental chronic cyclosporine nephropathy. Kidney Int 49: 1141-1151, 1996.
37. Shihab FS, Bennett WM, Yi H, and Andoh TF. Expression of vascular endothelial growth factor and its receptors Flt-1 and KDR/Flk-1 in chronic cyclosporine nephrotoxicity. Transplantation 72: 164-168, 2001.
38. Tsai JC, Teng LJ, Chen CT, Hong TM, Goldman CK, and Gillespie GY. Protein kinase C mediates induced secretion of vascular endothelial growth factor by human glioma cells. Biochem Biophys Res Commun 309: 952-960, 2003.
39. Yamamoto T, Kozawa O, Tanabe K, Akamatsu S, Matsuno H, Dohi S, and Uematsu T. Involvement of p38 MAP kinase in TGF-β-stimulated VEGF synthesis in aortic smooth muscle cells. J Cell Biochem 82: 591-598, 2001.
40. Zhang H, Akman HO, Smith EL, Zhao J, Murphy-Ullrich JE, and Batuman OA. Cellular response to hypoxia involves signaling via Smad proteins. Blood 101: 2253-2260, 2003.